SAN DIEGO, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present at the following upcoming conferences in December:
- Piper Jaffray 25th Annual Healthcare Conference on Tuesday, December 3, 2013 at 4:30 pm ET. The conference will be held at the New York Palace Hotel in New York City.
- Oppenheimer & Co. 24th Annual Healthcare Conference on Wednesday, December 11, 2013 at 7:45 am ET. The conference will be held at the Crowne Plaza Times Square in New York City.
A live audio webcast of each presentation will be available on the Investor section of the company's website at http://ir.conatuspharma.com/events.cfm, where it will be archived for 30 days.
About Emricasan Clinical Development
Conatus is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. To date, emricasan has been studied in over 500 subjects in ten clinical trials. In a randomized Phase 2b clinical trial, emricasan demonstrated a statistically significant, consistent, rapid and sustained reduction in elevated levels of two key biomarkers of inflammation and cell death that are implicated in the severity and progression of liver disease. Emricasan is currently in a Phase 2b clinical trial in patients with acute-on-chronic liver failure, as well as a Phase 2 clinical trial in patients with severe alcoholic hepatitis.
About Conatus Pharmaceuticals Inc.
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing emricasan as a first-in class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease. For additional information, please visit www.conatuspharma.com.
CONTACT: Paul Cox, Stern Investor Relations (212) 362-1200, email@example.comSource:Conatus Pharmaceuticals